Targets › ABCB1
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2026.
Translocates phospholipids and drugs across the membrane. Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. (UniProt, P08183)
Open in Phaseline: the race on ABCB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Texas Tech University Health Sciences Center | Curcumin Polyphenolic compound targeting amyloid-beta aggregation and tau pathology; crosses blood- | ABCB1, APP, MAPT | Phase 1 | Bioavailability | Dec 2026 |
Bioavailability (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.